DE3856440D1 - Modularer Zusammenbau von Antikörpergenen, dadurch hergestellte Antikörper und deren Anwendungen - Google Patents

Modularer Zusammenbau von Antikörpergenen, dadurch hergestellte Antikörper und deren Anwendungen

Info

Publication number
DE3856440D1
DE3856440D1 DE3856440T DE3856440T DE3856440D1 DE 3856440 D1 DE3856440 D1 DE 3856440D1 DE 3856440 T DE3856440 T DE 3856440T DE 3856440 T DE3856440 T DE 3856440T DE 3856440 D1 DE3856440 D1 DE 3856440D1
Authority
DE
Germany
Prior art keywords
applications
antibodies produced
antibody genes
modular assembly
region modules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE3856440T
Other languages
English (en)
Other versions
DE3856440T2 (de
Inventor
Randy R Robinson
Arnold H Horwitz
Alvin Y Liu
Randolph Wall
Marc Better
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Corp
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22138605&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3856440(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of DE3856440D1 publication Critical patent/DE3856440D1/de
Application granted granted Critical
Publication of DE3856440T2 publication Critical patent/DE3856440T2/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
DE3856440T 1987-07-24 1988-07-25 Modularer Zusammenbau von Antikörpergenen, dadurch hergestellte Antikörper und deren Anwendungen Ceased DE3856440T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7752887A 1987-07-24 1987-07-24

Publications (2)

Publication Number Publication Date
DE3856440D1 true DE3856440D1 (de) 2000-12-07
DE3856440T2 DE3856440T2 (de) 2001-06-13

Family

ID=22138605

Family Applications (4)

Application Number Title Priority Date Filing Date
DE3888186T Expired - Lifetime DE3888186T3 (de) 1987-07-24 1988-07-25 Modulärer zusammenbau von antikörpergenen, dadurch hergestellte antikörper und deren anwendung.
DE3856440T Ceased DE3856440T2 (de) 1987-07-24 1988-07-25 Modularer Zusammenbau von Antikörpergenen, dadurch hergestellte Antikörper und deren Anwendungen
DE3855421T Expired - Lifetime DE3855421T2 (de) 1987-07-24 1988-07-25 Modularer Zusammenbau von Antikörpergenen, dadurch hergestellte Antikörper und deren Anwendung
DE200812000039 Pending DE122008000039I1 (de) 1987-07-24 1988-07-25 Modularer Zusammenbau von Antikorpergenen, dadurchhergestellte Antikorper und deren Anwendungen.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE3888186T Expired - Lifetime DE3888186T3 (de) 1987-07-24 1988-07-25 Modulärer zusammenbau von antikörpergenen, dadurch hergestellte antikörper und deren anwendung.

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE3855421T Expired - Lifetime DE3855421T2 (de) 1987-07-24 1988-07-25 Modularer Zusammenbau von Antikörpergenen, dadurch hergestellte Antikörper und deren Anwendung
DE200812000039 Pending DE122008000039I1 (de) 1987-07-24 1988-07-25 Modularer Zusammenbau von Antikorpergenen, dadurchhergestellte Antikorper und deren Anwendungen.

Country Status (8)

Country Link
EP (3) EP0550400B1 (de)
JP (1) JP2991720B2 (de)
AT (2) ATE140266T1 (de)
AU (1) AU632462B2 (de)
CA (1) CA1341235C (de)
DE (4) DE3888186T3 (de)
DK (1) DK174824B1 (de)
WO (1) WO1989000999A1 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
DE3744595A1 (de) * 1987-12-31 1989-07-13 Andreas Dr Plueckthun Verfahren zur gentechnischen herstellung von antikoerpern
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
WO1989006283A1 (en) * 1988-01-11 1989-07-13 Ingene (International Genetic Engineering, Inc.) Novel plasmid vector with pectate lyase signal sequence
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ATE249840T1 (de) * 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
JP2002514919A (ja) * 1997-04-04 2002-05-21 バイオサイト ダイアグノスティックス，インコーポレイテッド 多価ライブラリーおよびポリクローナルライブラリー
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
EA004107B1 (ru) 1998-08-11 2003-12-25 Айдек Фармацевтикалс Корпорэйшн Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
DK1616572T3 (da) 1998-11-09 2010-12-06 Biogen Idec Inc Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
CA2400622A1 (en) 2000-02-24 2001-08-30 Eidgenossische Technische Hochschule Zurich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US6875590B2 (en) 2000-06-05 2005-04-05 Corixa Corporation Leader peptides for enhancing secretion of recombinant protein from a host cell
EP1749889A1 (de) * 2000-06-05 2007-02-07 Corixa Corporation Leader-Anteile zur Erhöhung der Sekretion von rekombinanten Proteinen aus einer Wirtzelle
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7858559B2 (en) 2000-11-17 2010-12-28 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
DK1356052T3 (da) * 2000-12-14 2008-12-08 Genentech Inc Produktion af hele antistoffer i prokaryotiske celler
MXPA03005271A (es) 2000-12-14 2003-09-25 Genentech Inc Cepas huesped bacteriales.
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
WO2003007889A2 (en) 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
NZ530852A (en) 2001-08-27 2006-11-30 Genentech Inc Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells
US20040052779A1 (en) * 2001-12-21 2004-03-18 Stinson Jeffrey R. Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
ATE501266T1 (de) * 2006-09-22 2011-03-15 Wacker Chemie Ag Verfahren zur fermentativen herstellung von antikörpern
EP2592147A1 (de) 2007-10-12 2013-05-15 F. Hoffmann-La Roche AG Proteinexpression von mehreren Nukleinsäuren
EP2303318A2 (de) 2008-06-20 2011-04-06 Wyeth LLC Zusammensetzungen und verfahren zur verwendung von orf 1358 von beta-hämolytischen streptokokken-stämmen
CA2733642A1 (en) 2008-08-14 2010-02-18 Cephalon Australia Pty Ltd Anti-il-12/il-23 antibodies
BRPI1011195B1 (pt) 2009-05-20 2020-10-13 Novimmune S.A métodos para produzir uma coleção de ácidos nucleicos
WO2014175164A1 (ja) 2013-04-25 2014-10-30 株式会社カネカ Ｆａｂ型抗体の分泌量を増大できるＦｄ鎖遺伝子又はＬ鎖遺伝子
CN106661107B (zh) 2013-12-24 2021-12-24 杨森制药公司 抗vista抗体及片段
WO2015135884A1 (en) 2014-03-10 2015-09-17 Richter Gedeon Nyrt. Immunoglobulin purification using pre-cleaning steps
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
EP3413910A1 (de) 2016-02-12 2018-12-19 Janssen Pharmaceutica NV Anti-vista (b7h5)-antikörper
CN109071653A (zh) 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP2020500152A (ja) 2016-09-30 2020-01-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する安全かつ有効な方法
MX2019005661A (es) 2016-11-16 2019-10-07 Janssen Biotech Inc Método para tratar la psoriasis con el anticuerpo específico anti-il23.
MX2019008989A (es) 2017-01-30 2019-10-09 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa.
CN110418652A (zh) 2017-02-07 2019-11-05 詹森生物科技公司 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
NZ756132A (en) 2017-03-10 2022-02-25 Hoffmann La Roche Method for producing multispecific antibodies
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
EP3762015A4 (de) 2018-03-05 2022-04-27 Janssen Biotech, Inc. Verfahren zur behandlung von morbus crohn mit anti-il23-spezifischem antikörper
JP2021530697A (ja) 2018-07-18 2021-11-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
BR112021005467A2 (pt) 2018-09-24 2021-06-22 Janssen Biotech, Inc. método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
CN113395979A (zh) 2018-11-20 2021-09-14 詹森生物科技公司 用抗il-23特异性抗体治疗银屑病的安全且有效的方法
MA54562A (fr) 2018-12-18 2021-10-27 Janssen Biotech Inc Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
AU2020208828A1 (en) 2019-01-15 2021-08-05 Janssen Biotech, Inc. Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
EA202192038A1 (ru) 2019-01-23 2021-10-05 Янссен Байотек, Инк. Композиции антител к фно для применения в способах лечения псориатического артрита
EP3938391A1 (de) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Verfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
EA202192508A1 (ru) 2019-03-14 2022-03-29 Янссен Байотек, Инк. Способы получения композиций антитела к фно
CA3133381A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
CA3133395A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
KR20210141583A (ko) 2019-03-18 2021-11-23 얀센 바이오테크 인코포레이티드 항-il-12/il-23 항체를 사용한 소아 대상의 건선 치료 방법
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
KR20220029593A (ko) 2019-06-03 2022-03-08 얀센 바이오테크 인코포레이티드 건선성 관절염의 치료를 위한 항-tnf 항체 조성물, 및 방법
JP2022535534A (ja) 2019-06-03 2022-08-09 ヤンセン バイオテツク，インコーポレーテツド 活動性強直性脊椎炎を治療するための抗ｔｎｆ抗体、組成物、及び方法
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
EP4305062A1 (de) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Verfahren zur behandlung von patienten mit psoriasisarthritis mit unzureichender reaktion auf eine tnf-therapie mit anti-il23-spezifischem antikörper
IL305802A (en) 2021-03-12 2023-11-01 Janssen Biotech Inc A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody
US20230040065A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
WO2023281463A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
KR20240034215A (ko) 2021-07-09 2024-03-13 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생산하기 위한 제조 방법
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS59187782A (ja) * 1983-04-09 1984-10-24 Kyowa Hakko Kogyo Co Ltd 免疫グロブリンをコ−ドする新規ｄｎａ
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) * 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
WO1989006283A1 (en) * 1988-01-11 1989-07-13 Ingene (International Genetic Engineering, Inc.) Novel plasmid vector with pectate lyase signal sequence

Also Published As

Publication number Publication date
DK19290D0 (da) 1990-01-24
DK174824B1 (da) 2003-12-08
DK19290A (da) 1990-03-23
JPH03501321A (ja) 1991-03-28
DE3888186T3 (de) 2000-08-24
CA1341235C (en) 2001-05-22
DE122008000039I1 (de) 2011-12-01
ATE140266T1 (de) 1996-07-15
EP0550400B1 (de) 1996-07-10
EP0731167A1 (de) 1996-09-11
EP0731167B1 (de) 2000-11-02
DE3856440T2 (de) 2001-06-13
DE3888186T2 (de) 1994-09-22
EP0371998B2 (de) 1999-11-03
EP0371998A4 (en) 1991-11-21
ATE197315T1 (de) 2000-11-15
AU632462B2 (en) 1993-01-07
DE3855421T2 (de) 1997-03-06
JP2991720B2 (ja) 1999-12-20
DE3888186D1 (de) 1994-04-07
EP0371998B1 (de) 1994-03-02
DE3855421D1 (de) 1996-08-14
WO1989000999A1 (en) 1989-02-09
EP0550400A2 (de) 1993-07-07
EP0550400A3 (en) 1993-10-06
EP0371998A1 (de) 1990-06-13
AU2324488A (en) 1989-03-01

Similar Documents

Publication Publication Date Title
DE3856440D1 (de) Modularer Zusammenbau von Antikörpergenen, dadurch hergestellte Antikörper und deren Anwendungen
DE69329877T2 (de) Von L Protein abgeleitete Immunoglobulin-bindende Proteine und deren anwendungen
KR920000789A (ko) 면역글로불린 부분을 갖는 융합 단백질, 이의 제조방법 및 용도
DE59914902D1 (de) Einzelkettiges, mehrfach-antigenbindendes Molekül, dessen Herstellung und Verwendung
ATE286126T1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
DE69434166D1 (de) Menschliche metabotropische glutamatrezeptor untertype hmglur7 und verwandte dns-verbindungen
DE3864585D1 (de) Dns-molekule, codierend fuer non-a-non-b-hepatitis-antigene und ihre verwendung zur herstellung dieser antigene.
DE58909458D1 (de) Antigenkonstrukte von "Major Histocompatibility Complex" Klasse I Antigenen mit spezifischen Trägermolekülen, ihre Herstellung und Verwendung.
ATE394484T1 (de) Smad 6 und dessen anwendungen
ATE140486T1 (de) Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
ATE193326T1 (de) Monoklonalantikörper, linker- und beta- glucuronidase enthaltende fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
CA2126182A1 (en) Humanized antibodies reactive with gpiib/iiia
EP0345550A3 (de) Hochmolekulare Arylensulfidpolymere
ATE286968T1 (de) Isolierung und verwendung von nukleinsäuremolekülen, welche für mitglieder der ssx-familie kodieren
DE68909515D1 (de) Durch antikoerper und liganden bewirkte zielrichtung von differentiationsinduktoren auf tumorzellen.
DE3876114D1 (de) Benzodioxol-derivate, diese enthaltende zusammensetzungen und deren verwendung zur herstellung von medikamenten.
FI880986A0 (fi) Tendamistatderivat.
DE69838459D1 (de) Für den licht-überempfinlichkeitsphaenotyp kodierende nukleotidsequenzen von tomaten, dadurch kodierte proteine und deren verwendungen
ATE102249T1 (de) Modulaerer zusammenbau von antikoerpergenen, dadurch hergestellte antikoerper und deren anwendung.

Legal Events

Date Code Title Description
SPC2 Refusal decision in registration proceedings for a supplementary protection certificate (spc)
R003 Refusal decision now final

Free format text: PRODUCT NAME: CERTOLIZUMAB PEGOL, (ARZNEIMITTEL CIMZIA) INCL. ALLE VERSCHIEDENEN FORMEN UND POST-TRA: 57856 20070907 NSLATIONEN MODIFIKATIONEN VON CERTOLUZIMAB PEGOL, SOWIE SALZE UND ESTER DAVON.; REGISTRATION NO/DATE

Spc suppl protection certif: 122008000039

Filing date: 20080723

Expiry date: 20080726